Article
Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 15 Dec 2014
Howe Anita Y M, Black Stuart, Curry Stephanie, Ludmerer Steven W, Liu Rong, Barnard Richard J O, Newhard William, Hwang Peggy M T, Nickle David, Gilbert Christopher, Caro Luzelena, DiNubile Mark J, Mobashery Niloufar
Abstract excerpt
BACKGROUND: Virologic failure following treatment of hepatitis C virus (HCV) genotype 1 with direct-acting antiviral agents is often accompanied by the emergence of resistant variants. MK-5172 is an investigational once-daily protease inhibitor. We analyzed variants in treatment-naive noncirrhotic patients with virologic failure on MK-5172 (100-800 mg/day) plus pegylated interferon alfa/ribavirin (peg-IFN/RBV)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.